KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic–predictive relevance of KRAS status, determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jian-Ming, Liu, Xiao-Jing, Ge, Fei-Jiao, Lin, Li, Wang, Yan, Sharma, Manish R, Liu, Ze-Yuan, Tommasi, Stefania, Paradiso, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272803/
https://www.ncbi.nlm.nih.gov/pubmed/25491325
http://dx.doi.org/10.1186/s13046-014-0104-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272803/
https://www.ncbi.nlm.nih.gov/pubmed/25491325
http://dx.doi.org/10.1186/s13046-014-0104-7

Ejemplares similares